XERMELO, also known by its generic name telotristat ethyl, is a prescription medication designed to treat certain symptoms associated with carcinoid syndrome, particularly when the syndrome is not adequately controlled by somatostatin analog (SSA) therapy alone. Carcinoid syndrome is a group of symptoms sometimes seen in patients with neuroendocrine tumors, including severe diarrhea and flushing. XERMELO works by inhibiting the enzyme tryptophan hydroxylase, which is involved in the production of serotonin. By reducing the production of serotonin within neuroendocrine tumor cells, XERMELO can help manage the debilitating diarrhea often associated with carcinoid syndrome. It is typically administered in tablet form and is intended for use in combination with SSA therapy to provide a more comprehensive approach to managing the symptoms of carcinoid syndrome.